Novocure reported second quarter 2026 net revenues of $183.6 million, a 16% year-over-year increase, driven by global active patient growth. The company also updated its full-year 2026 guidance, raising total net revenue to a range of $710 million - $725 million and Adjusted EBITDA to $0 million - $15 million. Novocure is a global oncology company that develops and commercializes Tumor Treating Fields (TTFields) therapy.
